Octreotide in the Management of Hormone-Refractory Prostate Cancer

Publisher： Karger

E-ISSN： 1421-9794|47|2|109-126

ISSN： 0009-3157

Source： Chemotherapy, Vol.47, Iss.2, 2001-03, pp. : 109-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In vivo Evidence of γ-Tocotrienol as a Chemosensitizer in the Treatment of Hormone-Refractory Prostate Cancer

By  

Pharmacology, Vol. 85, Iss. 4, 2010-04 ,pp. : 248-258

Karger

Access to resources Recommend Favorite

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment

By Guérin Olivier   Fischel Jean Louis   Ferrero Jean-Marc   Bozec Alexandre   Milano Gerard  

Pharmaceuticals, Vol. 3, Iss. 7, 2010-07 ,pp. : 2238-2247

MDPI

Access to resources Recommend Favorite

Gastrointestinal Cancer Refractory to Chemotherapy: A Role for Octreotide?

By  

Chemotherapy, Vol. 47, Iss. 2, 2001-03 ,pp. : 127-133

Karger

Access to resources Recommend Favorite

Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment

By  

Pharmacology, Vol. 85, Iss. 2, 2010-02 ,pp. : 110-120

Karger

Access to resources Recommend Favorite

The Palliative Effects of Octreotide in Cancer Patients

By  

Chemotherapy, Vol. 47, Iss. 2, 2001-03 ,pp. : 54-61

Karger

Access to resources Recommend Favorite